Sinoway Industrial Co., Ltd.

Therapeutic Effect of Nicotinamide Mononucleotide on Obesity Therapeutic Effect of Nicotinamide Mononucleotide on Obesity

Obesity is closely related to the development of type 2 diabetes. Type 2 diabetes is mainly due to the lack of sufficient insulin and decreased sensitivity of glucose metabolism tissue to insulin.. Obesity leads to dysfunction of adipose tissue, increased release of pro-inflammatory cytokines, and increased secretion of lipase. These all contribute to islet beta cell damage. Nicotinamide mononucleotide improves islet dysfunction and restores insulin secretion by catalyzing the biosynthesis of mammalian NAD+. The CAS number of nicotinamide mononucleotide is 1094-61-7. The study found that Nampt and NMN have no direct effect on the viability of human islet β cells and will not cause apoptosis. But they can strengthen glucose-stimulated insulin secretion and increase the level of NAD+. Exercise is an effective means of resisting obesity. This is due to the increase in NAD+ levels caused by exercise and enhanced mitochondrial energy metabolism. NMN can also increase the level of NAD+, so theoretically, NMN can achieve the same weight loss effect as exercise. The researchers compared intraperitoneal injections of NMN mice with exercised mice. The results showed that supplementation with NMN increased fat catabolism and increased NAD+ levels in the liver, while exercise primarily increased NAD+ levels in muscle. This suggests the possibility of NMN being used to treat obesity-related liver diseases such as nonalcoholic fatty liver disease based on the premise of NAD+.
Related News
  • TEL:+86-0592-5853819
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//